FDA and Vera Therapeutics Adjust Clinical Study Assessment for Atacicept
What happened
Vera Therapeutics reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept for adults with IgA nephropathy. The study showed atacicept produced a placebo-adjusted eGFR difference of 5.6 mL/min at week 52 and 11.1 mL/min at week 104. Separately, the FDA and Vera Therapeutics agreed to adjust the assessment of the clinical study.
From dailypolitical.com
Why it matters
The trial results indicate that atacicept may slow the annual loss of kidney function in patients with IgA nephropathy. This positive clinical outcome could influence investor confidence in Vera Therapeutics.
From dailypolitical.com
Who's involved
- FDARegulatory agency that agreed to adjust the clinical study assessment.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Jefferies Financial GroupSpeculative
Might see changes in market price or investor confidence due to the positive clinical data.